Cyproheptadine

Cyproheptadine Hydrochloride


Chartwell Rx, Llc
Human Prescription Drug
NDC 62135-949
Cyproheptadine also known as Cyproheptadine Hydrochloride is a human prescription drug labeled by 'Chartwell Rx, Llc'. National Drug Code (NDC) number for Cyproheptadine is 62135-949. This drug is available in dosage form of Syrup. The names of the active, medicinal ingredients in Cyproheptadine drug includes Cyproheptadine Hydrochloride - 2 mg/5mL . The currest status of Cyproheptadine drug is Active.

Drug Information:

Drug NDC: 62135-949
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Cyproheptadine
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Cyproheptadine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Chartwell Rx, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Syrup
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CYPROHEPTADINE HYDROCHLORIDE - 2 mg/5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Jul, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 13 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA203191
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Chartwell RX, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:866021
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0362135949945
UPC stands for Universal Product Code.
UNII:NJ82J0F8QC
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62135-949-47473 mL in 1 BOTTLE (62135-949-47)13 Jul, 2022N/ANo
62135-949-94946 mL in 1 BOTTLE (62135-949-94)13 Jul, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Cyproheptadine cyproheptadine hydrochloride peppermint alcohol anhydrous citric acid d&c yellow no. 10 butylated hydroxyanisole sucralose propylene glycol water trisodium citrate dihydrate sorbic acid cyproheptadine hydrochloride cyproheptadine

Indications and Usage:

Indications and usage perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild, uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Warnings:

Warnings children: overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions and death. antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. cns depressants: antihistamines may have additive effects with alcohol and other cns depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. activities requiring mental alertness: patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.

Dosage and Administration:

Dosage and administration dosage should be individualized according to the needs and the response of the patient. although intended primarily for administration to children, the syrup is also used for administration to adults who cannot swallow tablets. children: the total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m 2 ). age 2 to 6 years: the usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. the dose is not to exceed 12 mg a day. age 7 to 14 years: the usual dose is 4 mg (two teaspoonsful) two or three times a day, adjusted as necessary to the size and response of the patient. the dose is not to exceed 16 mg a day. adults: the total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). the therapeutic range is 4 to 20 mg a day, with the majority of patie
nts requiring 12 to 16 mg a day. an occasional patient may require as much as 32 mg a day for adequate relief. it is suggested that dosage be initiated with 4 mg (two teaspoonsful) three times a day and adjusted according to the size and response of the patient.

Contraindications:

Contraindications newborn or premature infants: this drug should not be used in newborn or premature infants. nursing mothers: because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. other conditions: hypersensitivity to cyproheptadine and other drugs of similar chemical structure monoamine oxidase inhibitor therapy (see drug interactions ) angle-closure glaucoma stenosing peptic ulcer symptomatic prostatic hypertrophy bladder neck obstruction pyloroduodenal obstruction elderly, debilitated patients

Adverse Reactions:

Adverse reactions adverse reactions which have been reported with the use of antihistamines are as follows: central nervous system: sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness. integumentary: allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity. special senses: acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus. cardiovascular: hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock. hematologic: hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia. digestive system: dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice. genitourinary: urinary frequency, difficult urination, urinary retention, early menses. respiratory: dryness of nose and throat, thickening of br
onchial secretions, tightness of chest and wheezing, nasal stuffiness. miscellaneous: fatigue, chills, headache, increased appetite/weight gain.

Overdosage:

Overdosage antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in children. also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur. if vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac. if the patient is unable to vomit, perform gastric lavage followed by activated charcoal. isotonic or ½ isotonic saline is the lavage of choice. precautions against aspiration must be taken especially in infants and children. when life-threatening cns signs and symptoms are present, intravenous physostigmine salicylate may be considered. dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (see package circulars for physostigmine products.) saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content. stimulants should not be used. vasopressors may be used to treat hypotension. the oral ld 50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

Description:

Description each 5 ml (one teaspoonful) contains: cyproheptadine hydrochloride 2 mg inactive ingredients: alcohol 5% (v/v), citric acid, d&c yellow #10, butylated hydroxyanisole, peppermint flavor, sucralose, propylene glycol, purified water, sodium citrate, sorbic acid (0.1%, as preservative). cyproheptadine hydrochloride is an antihistaminic and antiserotonergic agent. cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.88, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. it is the sesquihydrate of 4-( 5h -dibenzo [ a,d ]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. the molecular formula of the anhydrous salt is c 21 h 21 n • hcl and the structural formula of the anhydrous salt is: "image description"

Clinical Pharmacology:

Clinical pharmacology cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites. pharmacokinetics and metabolism: after a single 4 mg oral dose of 14 c-labeled cyproheptadine hydrochloride in normal subjects, given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. at least 40% of the administered radioactivity was excreted in the urine. no detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine syrup. the principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. elimination is diminished in renal insufficiency.

How Supplied:

How supplied cyproheptadine hydrochloride syrup (cyproheptadine hydrochloride oral solution usp) 2 mg/5 ml in a yellow, peppermint-flavored vehicle is supplied in a 473 ml (16 fl oz) container (ndc 62135-949-47) and in a 946 ml (32 fl oz) container (ndc 62135-949-94). store at 20° to 25°c (68° to 77°f) excursion permitted to 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. dispense in a tight, light-resistant container as defined in the usp, with a child-resistant closure. manufactured for: chartwell rx, llc. congers, ny 10920 l70984 rev. 07/2022

Package Label Principal Display Panel:

Package label. principal display panel cyproheptadine-hcl - 473 ml - ndc 62135-949-47 - label cyproheptadine-hcl - 946 ml - ndc 62135-949-94 - label "image description" "image description"


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.